Transaction · 0001871714-26-000002

Giordano Christopher Thomas

Giordano Christopher Thomas, CEO, reported an open-market or private purchase at TENAX THERAPEUTICS, INC. involving 6000.000000 shares for an estimated $11250.00. Reported holdings after the transaction were 17324.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code PCEO
TENXTENAX THERAPEUTICS, INC.
Trade date
Sep 11, 2026
Filing date
Sep 16, 2026
View on SEC Insider profile
Disclosed value$11.2kShares × reported price
Shares traded6.00k$1.88 per share
Holdings after17.3kDirect
% of reported position traded52.98%This security and ownership context
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 11,324 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

TENX price since this filing

Daily closing prices, with the filing date and available return windows
TENX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -5.5%1w ago +6.6%1d ago +7.1%
Returns since7d +4.4%30d -17.0%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001871714-26-000002
Common Stock
Transaction date
Sep 11, 2026
Filed Sep 16, 2026, 01:38 AM · 5d delay
Shares
6,000 sh
$1.88 per share
Estimated value
$11.2k
Computed from shares × price
Holdings after
17,324 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
CEO Buy Cluster Buy Director Buy Direct Ownership Large Holdings Increase
Filing-only score

+52 points

Compact filing score computed from stored Form 4 facts. Version v1.

Strong filing signal

This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.

How this score is calculated
  • open_market_purchase+12 points

    transaction_code = P

    Code P is a discretionary open-market purchase.
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • ceo_buy+12 points

    is_officer + officer_title/role mentions CEO

    CEO open-market purchase.
  • cluster_buy+14 points

    cluster-buy signal matched

    Multiple insiders bought within the configured window.
  • large_holdings_increase+8 points

    large-holdings-increase signal matched

    Reported acquired shares meet the configured percentage of post-transaction holdings.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    This transaction was executed in multiple trades at prices ranging from $1.87 to $1.88. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide up…

  2. F2

    This transaction was executed in multiple trades at prices ranging from $1.82 to $1.83. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide up…

  3. F3

    The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest…

  4. F4

    The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on…

  5. F5

    The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subj…

  6. F6

    The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026,…

  7. F7

    The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025,…

Original filing · 0001871714-26-000002
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

TENX